{"name":"Manhattan Psychiatric Center","slug":"manhattan-psychiatric-center","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Fazaclo","genericName":"Fazaclo","slug":"fazaclo","indication":"Suicidal Behavior in Schizoaffective Disorder","status":"marketed"}]}],"pipeline":[{"name":"Fazaclo","genericName":"Fazaclo","slug":"fazaclo","phase":"marketed","mechanism":"Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E","indications":["Suicidal Behavior in Schizoaffective Disorder","Suicidal Behavior in Schizophrenia","Treatment-Resistant Schizophrenia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxQWEQ3d25Gb1Y1Y19nUXN4YW9NRlQ5NHdZYzRzYlhuQnRJMnMzSDRnVDVoUjE5Q0UyM1NSWDdFRExVVWdwc1piX1BwLUFhdjlHYmRqc0Q3ak5MODdRLUpCcExhYUh1UFZFTjJYTml5ckd4NnVMUzVYeEFlTy1VRXQtandLTU8wb0pkSi1fdlFHYzVDUGlXS3Bndld1RGdicGdoTlU5OEhLeWFULXZQallLcjItYUp4UzNNR0pGaWZOS3hMbFJJR041eXFNUzU?oc=5","date":"2025-05-12","type":"trial","source":"Psychiatric Times","summary":"Phase 3 Development Plan for Evenamide as Add-On Therapy for Treatment-Resistant Schizophrenia - Psychiatric Times","headline":"Phase 3 Development Plan for Evenamide as Add-On Therapy for Treatment-Resistant Schizophrenia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxPdlJjQ25Tck9lM1MwT3NlUE8wZVFROXpZcFpSM3lISzdoR1FMNER2cURHNXRlcXpvYnpQQVJHNlNKd2gtQ0l2VWk4U1RWVm1hbnZJNzZJd0RETVRENUpwM1FpcHhFc1MxQlE4TGxmVGRwdHdKNXFEUHY1TWwwWnFnNmFmNDBJcjFCNmM5UlpZY0VLbUhmR1RNVEptMW9wc2dfVEZLaGQ1QjBJbHpfSldNN01SOEpBUWg4ZFFwLWJLTERGU3lsYXoxdmRjaTNEd2xoM2l4LUItcExpZEF1MEJ5V0xIR2Y3RzFKenNCRURoWGxFb19KUzdkc1N0VW1fX1NzWElkRjlkaFpvckJaN1JYN0doemQ0T25fVVJVQUc3Yw?oc=5","date":"2025-05-12","type":"regulatory","source":"BioSpace","summary":"Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS) - BioSpace","headline":"Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Tre","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNdmp3bVJYNjdXQ0poVThIcTZoaFVmNXdxR3ZCWXZvX2U5MEtEU0tGSWNxQ0xydm9pRVRZRG01elc3Z1h0akhtWkprUzVQVkdtSGprZWlGcmJmWFRvSl8tQlNGbzE5S1pMUktsSWtIc3liQ2VfYTIwWU8zSXptRGRrTmc5Qkhqa2dOMHZkb1BpTjFOZFZHcDQ0NF9UWTN2SkdhcUE?oc=5","date":"2023-06-06","type":"pipeline","source":"NJ Spotlight News","summary":"Joe Masciandaro, mental health care innovator - NJ Spotlight News","headline":"Joe Masciandaro, mental health care innovator","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOLVNOQUZVbjdiVkxNWlZhSmc0NjBRYm9LTElQRDVWdHJ6S1d4RWJwcXA0SHNQTWlaM3NfN2l6U2RETGVmNEROdC01dm9YX2dLMFo0S0tjel9YSk9UYWdkRk05LS1jeGhZVUp6Q21XZ19yVFpMQ2N0RFpWWndPS0MxaldrajYxTlNtU3JENXVHcw?oc=5","date":"2021-12-22","type":"pipeline","source":"Grand View Research","summary":"U.S. Psychiatry Clinic Market Size | Industry Report, 2033 - Grand View Research","headline":"U.S. Psychiatry Clinic Market Size | Industry Report, 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOTDAzbkk4LXFoMnhLMmpiZ0hRS0VtRXNmZjhxNkYtaEY2RUpYNW4xeV9yLXNiYjl0X052OXRQU2dkWDQyZGpVdzhUanI5TWNOTV80NXZXZ3FhU3NtN1dwWHlwREZhU3pDcnA1TWx5RFdna0c3Y1ZRendoeC05UXdDQXhDbmtLTjJkOWFVMDBpVEJsNkNtODRKZ3l0Z2JNc3R5a2gyT0QwdFdDMjQ?oc=5","date":"2018-11-05","type":"pipeline","source":"WSJ","summary":"A Poll Site Set Up to Make Voting Easier for Vulnerable New Yorkers - WSJ","headline":"A Poll Site Set Up to Make Voting Easier for Vulnerable New Yorkers","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}